Urinary *Helicobacter pylori* infection: An Expanding Horizon

Mohammed S. Al-Marhoon

Urology Division, Department of Surgery, College of Medicine & Health Sciences, Sultan Qaboos University, P.O. Box 35, Al-Khoud 123, Oman

**Abstract**

What is *Helicobacter pylori* (*H. pylori*) and do we need to know about it as urologists. *H. pylori* infection is a focus of attention nowadays. It has been found to cause gastrointestinal disorders [1], and extraintestinal disorders [2]. The aim of this mini-review is to highlight the ongoing research addressing the question of whether *H. pylori* has a role to play in urological diseases, especially prostate and bladder cancers. Current studies have paved the way for further comprehensive studies to examine the association of *H. pylori* infection with BPH and prostate cancer. If *H. pylori* is found to have a significant role in urological diseases, prevention of bladder and prostate cancers by eradication of *H. pylori* infection may become a reality like what happened in the treatment of peptic ulcer disease and gastric cancer.

**Introduction**

The spiral shaped bacterium *H. pylori* is strongly associated with inflammation of the stomach and is also implicated in the development of gastric malignancy. *H. pylori* is associated with peptic ulcers and chronic gastritis in humans. It is associated with duodenal ulcers and has been associated with the development of adenocarcinoma and low grade lymphoma of mucosa associated lymphoid tissue in the stomach. More recently this bacterium has also been associated with urinary infections. Karafet et al. [3] in a pilot study reported that, seropositivity for antibody against *H. pylori* was significantly higher in the chronic gastritis/chronic pelvic pain syndrome (CP/CPPS) than the control group and supports the hypothesis that *H. pylori* may play a role in CP/CPPS. In addition, Cheng et al. [4] in a prospective study found that, men having a history of prostatitis had an increased risk of prostate cancer than men with no history (RR = 1.30; 95% CI: 1.10–1.54) and suggested that prostatitis may be involved in prostate cancer susceptibility. It is not clear how *H. pylori* is transmitted or why some patients become symptomatic while others do not. The bacteria are most likely spread from person to person through fecal to oral or oral to oral routes. Possible environmental sources include contaminated water reservoirs. *H. pylori* can exist in a number of locations: in the mucus; attached to epithelial cells; or inside of vacuoles in epithelial cells, where it produces adhesins that bind to membrane-associated lipids and carbohydrates in or on epithelial cells. Diagnosis of *H. pylori* is usually made by checking for dyspeptic symptoms and by tests which can indicate *H. pylori* infection. One can test noninvasively for *H. pylori* infection with a blood antibody test, stool antigen test, or with the carbon urea breath test (in which the patient drinks 14C- or 13C-labelled urea, which the bacterium metabolizes, producing labeled carbon dioxide that can be detected in the breath). However, the most reliable method for detecting *H. pylori* infection is a biopsy during endoscopy with a rapid urease test, histologic examination, and microbial culture.

It has been demonstrated that the prostate does not harbor normal bacterial flora by the absence of bacterial genomes in histologically normal prostates. The etiology of the chronic prostatitis/pelvic pain syndrome remains controversial, some believing that bacteria are present but do not appear on conventional aerobic cultures. A molecular technique to detect bacteria that do not grow in culture is to use PCR (Polymerase Chain Reaction) for bacterial 16S rDNA. Bacterial DNA sequences were found to be present in prostate biopsy specimens in 77% of men with chronic prostatitis/pelvic pain syndrome. Also 78% of prostatectomy specimens from men who had prostate cancer or BPH (benign prostate hyperplasia) were positive for bacterial DNA.

**Proposed mechanism of oncogenesis induced by *H. pylori***

The rationale of proposing a relation for *H. pylori* to bladder and prostate diseases are based on the following observations: *H. pylori* has been detected in other organs and correlates with other cancers. It has long been known that certain infectious agents that affect specific areas of the body can also have systemic sequelae. *H. pylori* infection is a triggering factor in the process of increasingly severe inflammation progressing from chronic active inflammation to atrophy, metaplasia, dysplasia and cancer. It was shown in a mouse model of chronic bacterial prostatitis induced by *Escherichia coli* that chronic inflammation leads to severe dysplasia and atypical hyperplasia in the prostate. Epidemiological studies show significant associations between infection and prostatic carcinoma. Also 78% of prostatectomy specimens from men who had prostate cancer or BPH were positive for bacterial DNA. It has been reported that MALT lymphoma of the urinary bladder disappeared after treatment with *H. pylori* eradication therapy. *H. pylori* was transurethrally inoculated into the mouse urinary tract, the organism established infection and induced inflammation in the urinary bladder and pelvis.

**H. pylori related ongoing research**

The possibility that a bacterium could cause gastritis, peptic ulcers and cancer was a difficult concept to accept, especially as it would change the whole concept of the pathophysiology of ulcer disease that was based on acid etiology. It is now clear that infection with *H. pylori* is associated with peptic ulcer disease and gastric cancer. *H. pylori* has been designated a group one (definitive) carcinogen by the World Health Organization. The pathways by which *H. pylori* leads to gastric cancer have been shown by models of gastric carcinogenesis. Correa’s multi-step model showed that *H. pylori* infection is a triggering factor in the process of increasingly severe gastric lesions progressing from chronic active gastritis to atrophy, intestinal metaplasia, dysplasia and gastric cancer. Al-Marhoon [5] proposed a model

---

**Corresponding Author:** Dr. Mohammed S. Al-Marhoon, Urology Division, Department of Surgery, College of Medicine & Health Sciences, Sultan Qaboos University, P.O. Box 35, Al-Khoud 123, Sultanate of Oman; Email: mslmarhoon@gmail.com


**Copyright:** © 2017 A-Marhoon. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
indicating the initial changes induced by \textit{H. pylori} infection that play a role in protecting the organism and enhancing its colonization in the stomach that may lead to gastric cancer. In addition, Al-Marhoon [6] reviewed the literature about \textit{H. pylori} and its relation to urological disorders, and found an accumulating evidence appearing in the literature relating \textit{H. pylori} infection to urological diseases. The most obvious is the implication of \textit{H. pylori} in inducing chronic cystitis leading to bladder lymphoma. [7] In addition, some epidemiological studies have shown significant associations between infective chronic prostatitis and prostatic carcinoma. [8] Recently, Al-Marhoon [9] have conducted a study to determine whether \textit{H. pylori} is detectable in both benign prostatic hyperplasia (BPH) and prostate cancer (PCa) by studying 100 consecutive patients with prostate diseases. Detection of \textit{H. pylori} DNA in prostate tissue from patients with BPH and PCa was performed using both immunohistochemistry and PCR, and the results were confirmed by DNA sequencing. In this study, 78% of patients had BPH and 19% had PCa. While immunohistochemistry showed no positive sample for \textit{H. pylori}, PCR combined with sequencing detected \textit{H. pylori} DNA in prostate tissue samples from 5 patients. However, statistical analysis of the data showed that BPH and PCa are not significantly associated with the presence of \textit{H. pylori} DNA in prostate tissue (odds ratio = 0.94, 95% confidence interval = 0.09–23.34, one-tailed Chi-square value = 0.660, p > 0.05). The limitation of this study was the small number of PCa patients. This study provided, for the first time, molecular evidence of the presence of \textit{H. pylori} DNA in prostatic tissue of patients with BPH and PCa.

Conclusion

Current studies have paved the way for further comprehensive studies to examine the association of \textit{H. pylori} infection with BPH and PCa. If \textit{H. pylori} is found to have a significant role in urological diseases, prevention of bladder and prostate cancers by eradication of \textit{H. pylori} infection may become a reality like what happened in the treatment of peptic ulcer disease and gastric cancer.

Competing Interests

The authors declare that they have no competing interests.

References